Head and Neck Neoplasm: Clinical Trials

5 trials for Head and Neck Neoplasm, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 terminated, 1 unknown. 5 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Completed 3, Terminated 1, Unknown 1
Phase 11Completed 1

Follow Head and Neck Neoplasm: new trials by email Literature Review of Head and Neck Neoplasm trials Research Report on Head and Neck Neoplasm

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.
Tolipalimab, Reirradiation - Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms
Phase 2UnknownSun Yat-sen University252019-05-012022-04-29
Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types
Nivolumab - Carcinoma, Renal Cell, Head and Neck Neoplasm
Phase 2CompletedUNICANCER2692017-06-162024-02-28
HARE-40: HPV Anti-CD40 RNA vaccinE
BNT113 - Human Papilloma Virus Related Carcinoma, Head and Neck Neoplasm
Phase 1 / Phase 2CompletedUniversity of Southampton302017-04-112026-10-07
Cetuximab as Induction Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)
Cetuximab, Docetaxel, Cisplatin - Head and Neck Neoplasm
Phase 2CompletedSeoul National University Hospital922008-04-012013-12-04
Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED)
Temozolomide - Colorectal Neoplasm, Head and Neck Neoplasm
Phase 2TerminatedMerck Sharp & Dohme LLC862007-01-262017-06-08

Narrower conditions

Head and Neck Neoplasms (5)  ·  Penile Neoplasms (2)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Renal Cell (1)  ·  Colorectal Neoplasms (1)  ·  Esophageal Neoplasms (1)  ·  Microsatellite Instability (1)  ·  Nasopharyngeal Carcinoma (1)  ·  Nasopharyngeal Diseases (1)  ·  Nasopharyngeal Neoplasms (1)  ·  Neoplasms, Unknown Primary (1)  ·  Skin Neoplasms (1)  ·  Uterine Cervical Neoplasms (1)

Broader conditions

Neoplasms (5)  ·  Neoplasms by Site (5)  ·  Carcinoma (2)  ·  Female Urogenital Diseases (2)  ·  Female Urogenital Diseases and Pregnancy Complications (2)  ·  Genital Diseases (2)  ·  Genital Diseases, Male (2)  ·  Genital Neoplasms, Male (2)  ·  Male Urogenital Diseases (2)  ·  Neoplasms by Histologic Type (2)  ·  Neoplasms, Glandular and Epithelial (2)  ·  Pathologic Processes (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Penile Diseases (2)  ·  Urogenital Diseases (2)

Interventions

Cetuximab (1)  ·  Cisplatin (1)  ·  Docetaxel (1)  ·  Nivolumab (1)  ·  Re-Irradiation (1)  ·  Temozolomide (1)

Sponsors

Merck Sharp & Dohme LLC (1)  ·  Seoul National University Hospital (1)  ·  Sun Yat-sen University (1)  ·  UNICANCER (1)  ·  University of Southampton (1)

Countries

China (1)  ·  France (1)  ·  South Korea (1)  ·  United Kingdom (1)

Top investigators

Christian Ottensmeier, Prof (1)  ·  Dae Seog Heo, Prof. (1)  ·  Ioannis Karydis, Dr (1)  ·  Ming-Yuan Chen, MD,PhD (1)

Results publications

PMID 23443801, PMID 26304911, PMID 34782428

NIH funding

2014 (1), 2016 (1)